Ken Griffin
RDY icon

Ken Griffin’s Dr. Reddy's Laboratories RDY Stock Holding History

Ken Griffin’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,100
Closed -$27.7K – 14639
2025
Q1 		$27.7K Sell
2,100
-3,800
-64% -$52.4K ﹤0.01% 12896
2024
Q4 		$93.2K Sell
5,900
-11,100
-65% -$167K ﹤0.01% 11581
2024
Q3 		$270K Sell
17,000
-13,000
-43% -$209K ﹤0.01% 9542
2024
Q2 		$457K Buy
30,000
+1,500
+5% +$21.5K ﹤0.01% 8235
2024
Q1 		$418K Buy
28,500
+13,500
+90% +$197K ﹤0.01% 8774
2023
Q4 		$209K Buy
15,000
+1,500
+11% +$20.1K ﹤0.01% 9872
2023
Q3 		$181K Buy
13,500
+10,000
+286% +$135K ﹤0.01% 10088
2023
Q2 		$44.2K Sell
3,500
-10,000
-74% -$117K ﹤0.01% 11947
2023
Q1 		$154K Buy
13,500
+9,000
+200% +$97.1K ﹤0.01% 10601
2022
Q4 		$46.6K Buy
+4,500
New +$48.5K ﹤0.01% 12224
2022
Q2 		– Sell
-38,000
Closed -$424K – 13890
2022
Q1 		$424K Buy
38,000
+10,000
+36% +$113K ﹤0.01% 9777
2021
Q4 		$366K Buy
28,000
+1,000
+4% +$12.6K ﹤0.01% 10463
2021
Q3 		$352K Sell
27,000
-11,500
-30% -$153K ﹤0.01% 10711
2021
Q2 		$566K Buy
+38,500
New +$538K ﹤0.01% 9785
2021
Q1 		– Sell
-28,500
Closed -$406K – 13626
2020
Q4 		$406K Sell
28,500
-16,000
-36% -$215K ﹤0.01% 8540
2020
Q3 		$619K Buy
44,500
+21,000
+89% +$250K ﹤0.01% 6907
2020
Q2 		$249K Buy
+23,500
New +$239K ﹤0.01% 8215
2019
Q3 		– Sell
-36,500
Closed -$274K – 9659
2019
Q2 		$274K Sell
36,500
-3,000
-8% -$23.6K ﹤0.01% 7719
2019
Q1 		$320K Buy
+39,500
New +$300K ﹤0.01% 7518
2018
Q2 		– Sell
-85,500
Closed -$559K – 9206
2018
Q1 		$559K Buy
85,500
+38,000
+80% +$266K ﹤0.01% 5707
2017
Q4 		$357K Buy
+47,500
New +$342K ﹤0.01% 6169
2017
Q1 		– Sell
-34,000
Closed -$308K – 7930
2016
Q4 		$308K Buy
+34,000
New +$316K ﹤0.01% 5632

Other funds holding RDY

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AIM
Aikya Investment Management London, United Kingdom $341M AUM 28.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Ken Griffin's RDY Position: Q1 2026 in Review

Ken Griffin increased its Dr. Reddy's Laboratories (RDY) stake by 38% in Q1 2026, buying an estimated $1.7M and bringing the position to 446,606 shares worth $6.19M. The position accounts for ﹤0.01% of the portfolio, ranked #3996.

Ken Griffin first reported a position in RDY in Q4 2013 and has held it in 30 quarters since. The position peaked at $18.7M in Q2 2023. 249 funds tracked by Wall St. Rank hold RDY as of Q1 2026.

  • Ken Griffin held 446,606 shares of Dr. Reddy's Laboratories worth $6.19M as of Q1 2026.
  • Ken Griffin bought 122,157 Dr. Reddy's Laboratories shares in Q1 2026, an estimated $1.7M.
  • Dr. Reddy's Laboratories made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #3996 holding.
  • Ken Griffin first reported a position in Dr. Reddy's Laboratories in Q4 2013 and has held it in 30 quarters since.
  • Ken Griffin's Dr. Reddy's Laboratories position peaked at $18.7M in Q2 2023.
  • 249 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.